Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) plummeted as much as 11.69% in pre-market trading on Wednesday, October 31, 2024, after the biopharmaceutical company announced a potential $100 million common stock offering.
The stock sell-off came despite Travere reporting solid third-quarter 2024 financial results earlier in the day. The company's quarterly earnings per share of -$0.70 met analysts' consensus estimates, while revenue of $62.9 million beat expectations of $59.7 million, driven by a 69.56% year-over-year increase.
However, investors appeared to be more focused on the company's plans to raise additional capital through a stock sale. Issuing new shares typically dilutes the ownership stake of existing shareholders, which can put downward pressure on the stock price in the near term.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。